Lacosamide as monotherapy in focal seizure: Literature review
Abstract Lacosamide is a newer approved antiepileptic drug (AED) characterized by its novel pharmacodynamic profile. It is now approved by United States Food and Drug Administration for use as monotherapy in adults (aged >17 years) with focal seizures based on historical controlled trial by Wechs...
Saved in:
Published in | International journal of epilepsy Vol. 4; no. 1; pp. 55 - 58 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
A-12, Second Floor, Sector -2, NOIDA -201301, India
Elsevier India Pvt Ltd
01.06.2017
Thieme Medical and Scientific Publishers Private Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Abstract Lacosamide is a newer approved antiepileptic drug (AED) characterized by its novel pharmacodynamic profile. It is now approved by United States Food and Drug Administration for use as monotherapy in adults (aged >17 years) with focal seizures based on historical controlled trial by Wechsler RT et al in 2014. Randomized controlled trials on lacosamide monotherapy have demonstrated significant reduction in median seizure frequency. In addition, 50% responder rates for lacosamide was noted in half of the patients, with retention rate in two third of patients in 1 year follow up period. Adverse events reported in clinical trials were mostly mild to moderate in intensity. The most common adverse events were dizziness, headache, convulsion, nausea and fatigue while convulsion and dizziness were commonly responsible for drug discontinuation. Overall, lacosamide monotherapy can be a good treatment option in patients with focal seizure. |
---|---|
ISSN: | 2213-6320 2213-6339 |
DOI: | 10.1016/j.ijep.2016.12.006 |